Trials / Completed
CompletedNCT01625897
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
A Long-term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 125 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MP-214 | Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214 |
| DRUG | Risperidone | Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2012-06-22
- Last updated
- 2026-01-05
- Results posted
- 2021-04-13
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01625897. Inclusion in this directory is not an endorsement.